1 Duke Cancer Institute; UC San Diego Moores Cancer Center; University of Colorado Cancer Center; Memorial Sloan Kettering Cancer Center; Massachusetts General Hospital Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; University of Michigan Rogel Cancer Center; UCSF Helen Diller Family Comprehensive Cancer Center; Hereditary Colon Cancer Foundation; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Stanford Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Fox Chase Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; The University of Texas MD Anderson Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Moffitt Cancer Center; Mayo Clinic Cancer Center; Fred & Pamela Buffett Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Roswell Park Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; University of Alabama at Birmingham Comprehensive Cancer Center; University of Wisconsin Carbone Cancer Center; and National Comprehensive Cancer Network.
The NCCN Guidelines for Colorectal Cancer (CRC) Screening outline various screening modalities as well as recommended screening strategies for individuals at average or increased-risk of developing sporadic CRC. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize 2018 updates to the NCCN Guidelines, with a primary focus on modalities used to screen individuals at average-risk for CRC.
Provided content development and/or authorship assistance.